Bicycle Therapeutics plc (F:50BA) — Market Cap & Net Worth
Market Cap & Net Worth: Bicycle Therapeutics plc (50BA)
Bicycle Therapeutics plc (F:50BA) has a market capitalization of $230.38 Million (€197.05 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #16008 globally and #1530 in its home market, demonstrating a -4.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bicycle Therapeutics plc's stock price €3.92 by its total outstanding shares 50269082 (50.27 Million). Analyse 50BA cash flow conversion to see how efficiently the company converts income to cash.
Bicycle Therapeutics plc Market Cap History: 2019 to 2026
Bicycle Therapeutics plc's market capitalization history from 2019 to 2026. Data shows change from $455.47 Million to $230.38 Million (-13.91% CAGR).
Bicycle Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bicycle Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.45x
Bicycle Therapeutics plc's market cap is 4.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $455.47 Million | $13.80 Million | -$30.61 Million | 33.00x | N/A |
| 2020 | $863.92 Million | $10.39 Million | -$51.01 Million | 83.15x | N/A |
| 2021 | $2.91 Billion | $11.70 Million | -$66.82 Million | 249.21x | N/A |
| 2022 | $1.56 Billion | $14.46 Million | -$112.72 Million | 108.09x | N/A |
| 2023 | $952.07 Million | $26.98 Million | -$180.66 Million | 35.29x | N/A |
| 2024 | $781.64 Million | $35.27 Million | -$169.03 Million | 22.16x | N/A |
| 2025 | $323.23 Million | $72.59 Million | -$218.96 Million | 4.45x | N/A |
Competitor Companies of 50BA by Market Capitalization
Companies near Bicycle Therapeutics plc in the global market cap rankings as of May 5, 2026.
Key companies related to Bicycle Therapeutics plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Bicycle Therapeutics plc Historical Marketcap From 2019 to 2026
Between 2019 and today, Bicycle Therapeutics plc's market cap moved from $455.47 Million to $ 230.38 Million, with a yearly change of -13.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €230.38 Million | -28.73% |
| 2025 | €323.23 Million | -58.65% |
| 2024 | €781.64 Million | -17.90% |
| 2023 | €952.07 Million | -39.10% |
| 2022 | €1.56 Billion | -46.37% |
| 2021 | €2.91 Billion | +237.41% |
| 2020 | €863.92 Million | +89.68% |
| 2019 | €455.47 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Bicycle Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $230.38 Million USD |
| MoneyControl | $230.38 Million USD |
| MarketWatch | $230.38 Million USD |
| marketcap.company | $230.38 Million USD |
| Reuters | $230.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more